SynthesisJournal of the American Academy of Dermatology2017
Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.
Synthesis in Journal of the American Academy of Dermatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Drug induced hyperpigmentation: systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Serpentine supravenous hyperpigmentation induced by chemotherapy: a systematic review.Archives of dermatological research · 2024Pooled it
- Characterization and management of serpentine supravenous reaction: A nine-patient case series.JAAD case reports · 2026Article
- Melphalan-induced serpentine supravenous hyperpigmentation with associated venous thrombosis.Oxford medical case reports · 2026Article
- Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Corrective and Restorative Dermatology in Cancer Survivors: An Urgent Unmet Need!American journal of clinical dermatology · 2026Review
- Health-Related Quality of Life in Patients With a Head and Neck Sarcoma: A Mixed-Methods Study.Head & neck · 2025Article
- Nivolumab induced discolouration of the tongue: a case report.Immunotherapy · 2025Article
- Cabozantinib Cutaneous Toxicity-Comprehensive Review.Life (Basel, Switzerland) · 2025Review
- Targeted therapies induced depigmentation: a review.Frontiers in immunology · 2025Review
- Vitiligo: From mechanisms of disease to treatable pathways.Skin health and disease · 2024Review
- Drug-Induced Pigmentation: A Review.Drugs · 2024Review
- Skin Hypopigmentation in Hematology Disorders.Hematology reports · 2024Review
- Microbes, macrophages, and melanin: a unifying theory of disease as exemplified by cancer.Frontiers in immunology · 2024Review
- Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response.Frontiers in oncology · 2023Article
- A Likely Case of Abemaciclib-Induced Hyperpigmentation in a Patient With Metastatic Breast Cancer.Cureus · 2022Article
- Anticancer treatments and photosensitivity.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022Review
- Medication related to pigmentation of oral mucosa.Medicina oral, patologia oral y cirugia bucal · 2022Review
- Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2022Article
- Durable disease control and refractory bullous pemphigoid after immune checkpoint inhibitor discontinuation in metastatic renal cell carcinoma: A case report.Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundThe discovery of signaling networks that drive oncogenic processes has led to the development of targeted anticancer agents. The burden of pigmentary adverse events from these drugs is unknown.
objectiveTo conduct a systematic review and meta-analysis of published clinical trials and determine the incidence and risk of development of targeted therapy-induced pigmentary changes.
methodsA comprehensive search was conducted to identify studies reporting targeted therapy-induced pigmentary changes. The incidence and relative risk were calculated. Case reports and series were reviewed to understand clinical characteristics.
resultsA total of 8052 patients from 36 clinical trials were included. The calculated overall incidences of targeted cancer therapy-induced all-grade pigmentary changes in the skin and hair were 17.7% (95% confidence interval [CI], 11.9-25.4) and 21.5% (95% CI, 14.9-30.1), respectively. The relative risk of all-grade pigmentary changes of skin and hair were 93.7 (95% CI, 5.86-1497.164) and 20.1 (95% CI, 8.35-48.248). Across 53 case reports/series (N = 75 patients), epidermal growth factor receptor and breakpoint cluster region-abelson inhibitors were the most common offending agents. LIMITATIONS: Potential under-reporting and variability in oncologists reporting these events.
conclusionThere is a significant risk of development of pigmentary changes during treatment with targeted anticancer therapies. Appropriate counseling and management are critical to minimize psychosocial impairment and deterioration in quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.